These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 12618981)

  • 21. Vancomycin resistance in Staphylococcus aureus.
    John CC
    N Engl J Med; 1999 Jul; 341(3):207-8. PubMed ID: 10409039
    [No Abstract]   [Full Text] [Related]  

  • 22. [Methicillin-resistant Staphylococcus aureus (MRSA) -- case report].
    Linde H; Lehn N
    Dtsch Med Wochenschr; 2005 Mar; 130(11):581; quiz 589-92. PubMed ID: 15761786
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacokinetic considerations in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis.
    Toma MB; Smith KM; Martin CA; Rapp RP
    Orthopedics; 2006 Jun; 29(6):497-501. PubMed ID: 16786941
    [No Abstract]   [Full Text] [Related]  

  • 24. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy.
    Sakoulas G; Moellering RC; Eliopoulos GM
    Clin Infect Dis; 2006 Jan; 42 Suppl 1():S40-50. PubMed ID: 16323119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vancomycin therapy and the progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis.
    Gelfand MS; Cleveland KO
    South Med J; 2004 Jun; 97(6):593-7. PubMed ID: 15255429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New resistance in Staphylococcus aureus.
    Waldvogel FA
    N Engl J Med; 1999 Feb; 340(7):556-7. PubMed ID: 10021477
    [No Abstract]   [Full Text] [Related]  

  • 27. Limitations of vancomycin in the management of resistant staphylococcal infections.
    Kollef MH
    Clin Infect Dis; 2007 Sep; 45 Suppl 3():S191-5. PubMed ID: 17712746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.
    Nagura J; Kijima K; Kurazono M; Takahata S; Sugano T; Tanaka Y; Hirai Y; Yamada K; Takayama Y; Shitara E; Yonezawa M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3526-8. PubMed ID: 16048975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MRSA and osteomyelitis of the foot in diabetes.
    Game F; Jeffcoate W
    Diabet Med; 2004 Sep; 21 Suppl 4():16-9. PubMed ID: 15315521
    [No Abstract]   [Full Text] [Related]  

  • 30. Methicillin-resistant Staphylococcus aureus infection with intermediate sensitivity to vancomycin: a case report and literature review.
    Schairer J; Sankri-Tarbichi AG; Fairfax MR; Salimnia H; Guzman JA
    J Intensive Care Med; 2008; 23(5):338-41. PubMed ID: 18701528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants.
    Hageman JC; Liedtke LA; Sunenshine RH; Strausbaugh LJ; McDonald LC; Tenover FC;
    Clin Infect Dis; 2006 Sep; 43(5):e42-5. PubMed ID: 16886141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of vancomycin therapy for osteomyelitis on colonization by methicillin-resistant Staphylococcus aureus: lack of emergence of glycopeptide resistance.
    Bernard L; Vaudaux P; Vuagnat A; Stern R; Rohner P; Pittet D; Schrenzel J; Hoffmeyer P;
    Infect Control Hosp Epidemiol; 2003 Sep; 24(9):650-4. PubMed ID: 14510246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model.
    Yin LY; Calhoun JH; Thomas TS; Wirtz ED
    J Antimicrob Chemother; 2009 Feb; 63(2):357-60. PubMed ID: 19060292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of severe infections caused by Staphylococcus aureus: a change in the vancomycin paradigm?
    Aranha Camargo LF
    Shock; 2008 Oct; 30 Suppl 1():67-9. PubMed ID: 18704006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Failure of vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections.
    Howden BP; Johnson PD; Charles PG; Grayson ML
    Clin Infect Dis; 2004 Nov; 39(10):1544; author reply 1544-5. PubMed ID: 15546096
    [No Abstract]   [Full Text] [Related]  

  • 36. [Is the vancomycin resistance of Staphylococcus aureus left unnoticed?].
    Vuento R
    Duodecim; 1999; 115(19):2045-7. PubMed ID: 11941798
    [No Abstract]   [Full Text] [Related]  

  • 37. Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp.
    Ng J; Gosbell IB
    J Antimicrob Chemother; 2005 Jun; 55(6):1008-12. PubMed ID: 15845784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impending danger: community-acquired methicillin-resistant Staphylococcus aureus.
    Hensinger RN
    J Pediatr Orthop; 2006; 26(6):701-2. PubMed ID: 17065929
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.
    Charles PG; Ward PB; Johnson PD; Howden BP; Grayson ML
    Clin Infect Dis; 2004 Feb; 38(3):448-51. PubMed ID: 14727222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy for methicillin-resistant Staphylococcus aureus.
    Torres-Tortosa M; Caballero-Granado FJ; Canueto J
    N Engl J Med; 2006 Nov; 355(20):2153-4; author reply 2155. PubMed ID: 17120350
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.